Supriya Lifescience Ltd
Supriya Lifescience Ltd Company History
Supriya Lifesciences is primarily engaged in manufacturing of Bulk Drugs and Pharmaceutical Chemicals.
2008
Incorporation of the Company upon its conversion from a partnership firm to a public limited company
2008
2009
Started production of Ketamine Hydrochloride
2009
2010
CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate
2010
2011
IDL granted for Chlorphenamine Maleate
2011
2013
COFEPRIS and KFDA approval granted
2013
2014
USFDA approval granted
IDL granted for Brompheniramine Maleate
2014
2015
EUGMP and EDQM approval granted
2015
2017
CEP (Certificate of Sustainability) granted for Pheniramine Maleate
Second time USFDA approval granted
2017
2018
CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride
2018
2020
Third time USFDA approval
2020
2021
CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate
NMPA approval granted
Health Canada approval
2021
2022
Supriya Lifescience Limited has informed the Exchange regarding ''Intimation Regarding Captive Solar Project Agreement Signed with Enrich Energy Pvt. Ltd''.
2022
